Randomized, vehicle-controlled trials of topical 5-fluorouracil therapy for actinic keratosis treatment: An overview

Immunotherapy

Volumn 4, Issue 9, 2012, Pages 939-945

  Rhavar, Maral ^a   Lamel, Sonia A ^a   Maibach, Howard I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

actinic keratosis; double blinded trials; non melanoma skin cancer; randomized controlled trials; solar keratosis; topical 5 fluorouracil; vehicle

Indexed keywords

FLUOROURACIL;

ACTINIC KERATOSIS; CLEARANCE; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; FEMALE; FLUOROURACIL; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; PHARMACEUTICAL VEHICLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84867383670     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.93     Document Type: Review

References (42)

1. MacKie RM, Quinn AG. Non-melanoma skin cancer and other epidermal skin tumours. In: Rook's Textbook of Dermatology (Volume 2). Burns T, Breathnach S, Cox N, Griffiths C (Eds). Blackwell Publishing, Oxford, UK, 36-50 (2004).
2. Feldman SR, Fleischer AB. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 87(4), 201-207 (2011).
3. Menter A, Vamvakias G, Jorizzo J. One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses. Cutis 81(6), 509-516 (2008).
4. Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur. J. Dermatol. 16(6), 599-606 (2006).
5. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J. Invest. Dermatol. 115(2), 273-277 (2000). (Pubitemid 30637198)
6. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J. Am. Acad. Dermatol. 42(1 Pt 2), 8-10 (2000).
7. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J. Am. Acad. Dermatol. 42(1 Pt 2), 4-7 (2000).
8. Holmes C, Foley P, Freeman M, Chong AH. Solar keratosis: epidemiology, pathogenesis, presentation and treatment. Australas. J. Dermatol. 48(2), 67-74; quiz 75-76 (2007).
9. Glogau RG. The risk of progression to invasive disease. J. Am. Acad. Dermatol. 42(1 Pt 2), 23-24 (2000).
10. Gupta AK, Cooper EA, Feldman SR, Fleischer AB. A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. National Ambulatory Medical Care Survey. Cutis 70(Suppl. 2), 8-13 (2002).
11. Frost CA, Green AC. Epidemiology of solar keratoses. Br. J. Dermatol. 131(4), 455-464 (1994). (Pubitemid 24315411)
12. Chia A, Moreno G, Lim A, Shumack S. Actinic keratoses. Aust. Fam. Physician 36(7), 539-543 (2007).
13. Farage MA, Miller KW, Maibach HI. Neoplastic skin cancer. In: Textbook of Aging Skin. Springer, Berlin, Germany, 547-548 (2010).
14. Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis-an update. Br. J. Dermatol. 157(Suppl. 2), 18-20 (2007). (Pubitemid 350179624)
15. Ko CJ. Actinic keratosis: facts and controversies. Clin. Dermatol. 28(3), 249-253 (2010).
16. Garcia M, Jemal A, Ward EM et al. Global Cancer Facts & Figures 2007. American Cancer Society, GA, USA (2007).
17. Criscione VD, Weinstock MA, Naylor MF et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 115(11), 2523-2530 (2009).
18. Werschler WP. Considerations for use of fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients. J. Clin. Aesthet. Dermatol. 1(2), 22-27 (2008).
19. Drake LA, Ceilley RI, Cornelison RL et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J. Am. Acad. Dermatol. 32(1), 95-98 (1995).
20. Falkson G, Schultz EJ. Skin changes in patients treated with 5-fluorouracil. Br. J. Dermatol. 74(6), 229-236 (1962).
21. McGillis ST, Fein H. Topical treatment strategies for non-melanoma skin cancer and precursor lesions. Semin. Cutan. Med. Surg. 23(3), 174-183 (2004). (Pubitemid 39458105)
22. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J. Drugs Dermatol. 5(2), 133-139 (2006).
23. Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch. Dermatol. 140(7), 813-816 (2004). (Pubitemid 38917849)
24. Weiss J, Menter A, Hevia O et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 70(Suppl. 2), 22-29 (2002).
25. Jorizzo J, Stewart D, Bucko A et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 70(6), 335-339 (2002). (Pubitemid 41757441)
26. Pattison DI, Davies MJ. Actions of ultraviolet light on cellular structures. EXS (96), 131-157 (2006).
27. Nelson MA, Einspahr JG, Alberts DS et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett. 85(1), 23-29 (1994). (Pubitemid 24280158)
28. Oppel T, Korting HC. Actinic keratosis: the key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects. Skin Pharmacol. Physiol. 17(2), 67-76 (2004). (Pubitemid 38250513)
29. Newman MD, Weinberg JM. Topical therapy in the treatment of actinic keratosis and basal cell carcinoma. Cutis 79(Suppl. 4), 18-28 (2007).
30. Robins P, Gupta AK. The use of topical fluorouracil to treat actinic keratosis. Cutis 70(Suppl. 2), 4-7 (2002).
31. Maibach H, Gorouhi F . Treatment of actinic keratosis. In: Evidence Based Dermatology. Carlson S, Borrdeaux J (Eds). PMPH, CT, USA, 615-648 (2011).
32. Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin. Ther. 23(6), 908-920 (2001). (Pubitemid 32554572)
33. Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin. Ther. 23(6), 901-907 (2001). (Pubitemid 32554571)
34. Korman N, Moy R, Ling M et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two Phase III, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch. Dermatol. 141(4), 467-473 (2005). (Pubitemid 40547405)
35. Jorizzo J, Dinehart S, Matheson R et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J. Am. Acad. Dermatol. 57(2), 265-268 (2007). (Pubitemid 47048863)
36. Fariba I, Ali A, Hossein SA, Atefeh S, Atarzadeh Behbahan SA. Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study. Indian J. Dermatol. Venereol. Leprol. 72(5), 346-349 (2006). (Pubitemid 44579162)
37. Alirezai M, Dupuy P, Amblard P et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses. J. Am. Acad. Dermatol. 30(3), 447-451 (1994). (Pubitemid 24129437)
38. Kligman AL, Throne EG. Topical therapy of actinic keratosis with tretinoin. In: Retinoid in Cutaneous Malignancy. Marks R (Ed.). Blackwell Scientific Publications, Oxford, UK, 66-73 (1991).
39. Weinstock MA, Bingham SF, Cole GW et al. Reliability of counting actinic keratoses before and after brief consensus discussion: the VA Topical Tretinoin Chemoprevention (VATTC) trial. Arch. Dermatol. 137(8), 1055-1058 (2001). (Pubitemid 32756463)
40. Atkins D, Bang RH, Sternberg MR, Chen SC. Reliable methods to evaluate the burden of actinic keratoses. J. Invest. Dermatol. 126(3), 591-594 (2006). (Pubitemid 43255646)
41. Kaur RR, Alikhan A, Maibach HI. Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment. J. Dermatol. Treat. 21(5), 267-271 (2010).
42. Ponsford MW, Goodman G, Marks R. The prevalence and accuracy of diagnosis of non-melanotic skin cancer in Victoria. Australas. J. Dermatol. 24(2), 79-82 (1983). (Pubitemid 14222921)